NEWARK, N.J., Dec. 7, 2023 /PRNewswire/ -- Tilde Sciences, a specialty pharmaceutical company, announced today that it has acquired two medicines, Daraprim® and Vecamyl® from Vyera Pharmaceuticals.
Martin Shkreli’s former company Vyera Pharmaceuticals, once known as Turing and infamous for jacking up the price of anti-parasite drug Daparim overnight, is filing for bankruptcy.
Martin Shkreli is stuck with an injunction barring him from the industry that spawned his “Pharma Bro” nickname after he failed Monday to convince a federal judge in New York to put the ban on hold while he appeals.
Vyera Pharmaceuticals has agreed to pay up to $40 million to settle charges that it engaged in anticompetitive practices to ward off generics and maintain “monopoly profits” from its more than 4,000% overnight price hike on the toxoplasmosis med Daraprim, according to a release from the office of New York Attorney General Letitia James.
Martin Shkreli to go toe-to-toe with new FTC chair over Daraprim price spikes
As part of Martin Shkreli’s efforts to continue running his biotech business from behind bars, a searing new lawsuit in New York says the “Pharma Bro” manipulated his company’s board of directors for his own personal gain.